Company / Net Income
Terns Pharmaceuticals, Inc. Net Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$88.9M
FY2024
5-year range
-$90.2M / -$40.1M
FY2020-FY2024
Trend
+1.5%
vs FY2023
Sector context
#107 of 215
Health Care
What the data says
At -$89M, Terns Pharmaceuticals, Inc.'s net income ranks #107 of 215 in the Health Care sector. Net Income returned to growth in FY2024 after 3 years of decline, reaching -$89M.
Based on SEC 10-K filings.
-$89M in FY2024.
Declined from -$60M to -$89M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 215 in Health CareTop 50% of 215This company -$88.9M Sector average $431.3M
▼
-120.6% below sector average
Key checks
Key Insights
- In FY2024, net income increased 1.5% year-over-year.
- Ranks #107 out of 215 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$88.9M | +1.5% |
| FY2023 | -$90.2M | -49.5% |
| FY2022 | -$60.3M | -20.3% |
| FY2021 | -$50.2M | -25.2% |
| FY2020 | -$40.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026